2/25
08:03 am
pstv
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ [Yahoo! Finance]
Medium
Report
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ [Yahoo! Finance]
2/25
07:30 am
pstv
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
Medium
Report
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
2/6
07:12 pm
pstv
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) [Yahoo! Finance]
Low
Report
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) [Yahoo! Finance]
2/3
09:00 am
pstv
Plus Therapeutics (NASDAQ:PSTV) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $2.00 price target on the stock.
Low
Report
Plus Therapeutics (NASDAQ:PSTV) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $2.00 price target on the stock.
1/23
07:09 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/22
11:40 am
pstv
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript [Seeking Alpha]
Low
Report
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript [Seeking Alpha]
1/22
10:45 am
pstv
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization [Yahoo! Finance]
Low
Report
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization [Yahoo! Finance]
1/22
08:06 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its price target lowered by analysts at D. Boral Capital from $5.00 to $4.00. They now have a "buy" rating on the stock.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its price target lowered by analysts at D. Boral Capital from $5.00 to $4.00. They now have a "buy" rating on the stock.
1/22
07:45 am
pstv
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
Medium
Report
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
1/21
05:50 pm
pstv
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET [Yahoo! Finance]
Medium
Report
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET [Yahoo! Finance]
1/21
04:15 pm
pstv
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
Low
Report
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
1/14
08:00 am
pstv
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
High
Report
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
1/8
08:23 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
1/8
07:42 am
pstv
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases [Yahoo! Finance]
Medium
Report
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases [Yahoo! Finance]
1/8
07:30 am
pstv
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
Medium
Report
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
12/11
01:41 pm
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Low
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
12/11
08:06 am
pstv
Plus Therapeutics Expands CNSide Assay Platform to State of California [Yahoo! Finance]
Medium
Report
Plus Therapeutics Expands CNSide Assay Platform to State of California [Yahoo! Finance]
12/11
07:30 am
pstv
Plus Therapeutics Expands CNSide Assay Platform to State of California
Medium
Report
Plus Therapeutics Expands CNSide Assay Platform to State of California
12/9
07:30 am
pstv
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
Medium
Report
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants